Continual reassessment method for ordered groups

Biometrics

Volumn 59, Issue 2, 2003, Pages 430-440

  O'Quigley, John ^a   Paoletti, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Bayesian inference; Clinical trials; Continual reassessment method; Dose finding studies; Maximum tolerated dose; Ordered groups; Pharmacology; Phase I designs; Toxicity; Two sample problem

Indexed keywords

INFERENCE ENGINES; PATIENT TREATMENT;

BAYESIAN INFERENCE; CLINICAL TRIAL; CONTINUAL REASSESSMENT METHOD; DOSE FINDING; DOSE-FINDING STUDY; MAXIMUM TOLERATED DOSE; ORDERED GROUP; PHARMACOLOGY; PHASE I; PHASE I DESIGN; TWO-SAMPLE PROBLEMS;

BAYESIAN NETWORKS;

DOSE-RESPONSE RELATIONSHIP; TOLERANCE; TOXICITY;

ACUTE LEUKEMIA; BAYES THEOREM; DOSE CALCULATION; HUMAN; MAXIMUM TOLERATED DOSE; REVIEW; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0037869516     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1541-0420.00050     Document Type: Review

References (9)

1. Babb, J., Rogatko, A., and Zacks, S. (1998). Cancer phase 1 clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17, 1103-1120.
2. Møller, S. (1995). An extension of the CRM using a preliminary up and down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 14, 991-22.
3. O'Quigley, J. (2001). Continual reassessment method in cancer clinical trials. In Handbook of Statistics in Clinical Oncology, J. Crowley (ed), 35-72. New York: Marcel Dekker.
4. O'Quigley, J. and Shen, Z. L. (1996). Continual reassessment method: A likelihood approach. Biometrics 52, 163-174.
5. O'Quigley, J. and Reiner, E. (1998). A stopping rule for the continual reassessment method. Biometrika 85(3), 741-48.
6. O'Quigley, J., Shen, Z. L., and Gamst, A. (1999). Two sample continual reassessment method. Journal of Biopharmaceutical Statistics 9(1), 17-44.
7. Rosenblum, M. G., Verschraegen, C. F., Murray, J. L., Kudelka, A. P., Gano, J., Cheung, L., and Kavanagh, J. J. (1999). Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics. Clinical Cancer Response 5(5), 953-61.
8. Shen, L. Z. and O'Quigley, J. (1996). Consistency of continual reassessment method under model mispecification. Biometrika 83, 395-406.
9. Whitehead, J. (1997). Bayesian decision procedures with application to dose-finding studies. International Journal of Pharmaceutical Medicine 11, 201-208.